Strides Pharma Science Limited has informed the Exchange about Completion of US-FDA Inspection at the Company s flagship facility in Bangalore
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
USFDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at Strides Pharma's flagship Bangalore facility from May 12-20, 2026. At the conclusion of the inspection, FDA issued a Form 483 with five observations. Form 483 observations are notations made when investigators identify potential violations during inspections. The company has stated it will respond to these observations within the stipulated time frame. No warning letter or import alert has been issued at this stage. The company will inform the exchanges of any further updates.
The inspection completion is a routine event with no immediate material impact on operations or revenue. However, five observations indicate compliance gaps that need to be addressed — failure to resolve them adequately could eventually affect US market access for products from this facility.